Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline
Open accessThe DOI matches its Crossref record; 205 of the 222 references it cites were found in a registry or an index; 39 of the 219 sources its claims cite were checked for support.
Abstract
OBJECTIVE: This clinical practice guideline addresses the diagnosis and treatment of primary adrenal insufficiency. PARTICIPANTS: The Task Force included a chair, selected by The Clinical Guidelines Subcommittee of the Endocrine Society, eight additional clinicians experienced with the disease, a methodologist, and a medical writer. The co-sponsoring associations (European Society of Endocrinology and the American Association for Clinical Chemistry) had participating members. The Task Force received no corporate funding or remuneration in connection with this review. EVIDENCE: This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system to determine the strength of recommendations and the quality of evidence. CONSENSUS PROCESS: The evidence used to formulate recommendations was derived from two commissioned systematic reviews as well as other published systematic reviews and studies identified by the Task Force. The guideline was reviewed and approved sequentially by the Endocrine Society's Clinical Guidelines Subcommittee and Clinical Affairs Core Committee, members responding to a web posting, and the Endocrine Society Council. At each stage, the Task Force incorporated changes in response to written comments. CONCLUSIONS: We recommend diagnostic tests for the exclusion of primary adrenal insufficiency in all patients with indicative clinical symptoms or signs. In particular, we suggest a low diagnostic (and therapeutic) threshold in acutely ill patients, as well as in patients with predisposing factors. This is also recommended for pregnant women with unexplained persistent nausea, fatigue, and hypotension. We recommend a short corticotropin test (250 μg) as the "gold standard" diagnostic tool to establish the diagnosis. If a short corticotropin test is not possible in the first instance, we recommend an initial screening procedure comprising the measurement of morning plasma ACTH and cortisol levels. Diagnosis of the underlying cause should include a validated assay of autoantibodies against 21-hydroxylase. In autoantibody-negative individuals, other causes should be sought. We recommend once-daily fludrocortisone (median, 0.1 mg) and hydrocortisone (15-25 mg/d) or cortisone acetate replacement (20-35 mg/d) applied in two to three daily doses in adults. In children, hydrocortisone (∼8 mg/m(2)/d) is recommended. Patients should be educated about stress dosing and equipped with a steroid card and glucocorticoid preparation for parenteral emergency administration. Follow-up should aim at monitoring appropriate dosing of corticosteroids and associated autoimmune diseases, particularly autoimmune thyroid disease.
Overview
CoChat Summary
TL;DR
This Endocrine Society clinical practice guideline provides evidence-based recommendations for diagnosing and treating primary adrenal insufficiency (PAI), emphasizing a low diagnostic threshold, the 250-µg short corticotropin test as the diagnostic gold standard, and glucocorticoid/mineralocorticoid replacement with adrenal crisis prevention. It also highlights major evidence gaps, including sparse randomized trial data for replacement regimens and limited diagnostic accuracy studies specifically in PAI.
Key findings
- For diagnosis, the guideline recommends testing patients with indicative symptoms/signs and using the standard-dose 250-µg corticotropin stimulation test as the “gold standard”; peak cortisol below 500 nmol/L (18 µg/dL) at 30 or 60 minutes indicates adrenal insufficiency. The high-dose ACTH stimulation test had a sensitivity of 92% (95% CI, 81–97%) for PAI based on five studies; no studies were available for the low-dose test in PAI. If corticotropin testing is not feasible, a morning cortisol <140 nmol/L (5 µg/dL) plus ACTH is suggested as a preliminary test.
- Autoimmune adrenalitis is the most common cause of PAI, accounting for up to 90% in Western countries; 21-hydroxylase autoantibodies should be measured, and about 30% of CYP21A2 autoantibody-positive individuals progressed to overt PAI during 5-year follow-up. In autoantibody-negative individuals, other causes should be sought, including adrenoleukodystrophy in males via very-long-chain fatty acids and adrenal CT for infiltrative or malignant disease.
- In adults, recommended replacement is hydrocortisone 15–25 mg/d or cortisone acetate 20–35 mg/d in two or three divided doses, with fludrocortisone starting at 50–100 µg/d (median, 0.1 mg) for confirmed aldosterone deficiency. Prednisolone 3–5 mg/d is an alternative, while dexamethasone is suggested against. DHEA replacement may be tried for 6 months in women with low libido, depressive symptoms, and/or low energy despite optimized replacement.
- For adrenal crisis, immediate parenteral hydrocortisone 100 mg (50 mg/m² for children) is recommended, followed by 200 mg/24 h (50–100 mg/m²/d for children), plus fluid resuscitation. Reported adrenal crisis frequencies were 6.6 crises/100 patient-years in a retrospective analysis of 444 patients and 8.3 crises/100 patient-years in a prospective study of 768 patient-years, with a crisis mortality rate of 0.5/100 patient-years.
Methods
- This is a GRADE-based clinical practice guideline developed by an Endocrine Society Task Force with a methodologist and medical writer; recommendations are graded strong (“we recommend,” 1) or weak (“we suggest,” 2), with evidence quality from QEEE (very low) to QQQQ (high), plus ungraded best practice statements.
- Evidence came from two commissioned systematic reviews and other published systematic reviews/studies. The first review compared high-dose vs low-dose ACTH stimulation for diagnosis and found only five studies for high-dose ACTH in PAI and none for low-dose ACTH in PAI. The second review compared glucocorticoid replacement regimens and identified 15 observational studies; mortality, bone density, and adrenal crisis data were very sparse or unavailable, and there was no statistically significant HRQoL difference between hydrocortisone dosages ≥30 mg/d vs <30 mg/d.
- The guideline was reviewed and approved sequentially by Endocrine Society committees, members responding to a web posting, and the Endocrine Society Council; the Task Force received no corporate funding or remuneration.
Limitations
- The paper states that the evidence base is limited: there are no randomized controlled trials for many treatment questions, diagnostic accuracy data for high-dose ACTH in PAI come from only five studies with none for low-dose ACTH in PAI, and the second systematic review found sparse or unavailable data on mortality, bone density, and adrenal crisis, with very low-quality evidence for extended-release/dual-release glucocorticoids. Many recommendations are weak or ungraded best practice statements.
- The paper states that cortisol cutoff values after corticotropin stimulation vary by assay, ACTH assays have analytical bias, and actual clinical cutpoints should be based on assay-specific normative data.
- Evident from the text: the guideline focuses only on PAI and explicitly excludes secondary adrenal insufficiency and critical illness-related corticosteroid insufficiency; some recommendations rely on clinical experience, unsystematic observations, and values/preferences rather than direct systematic evidence.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Algorithm for the diagnostic approach to the patient with PAI. The most common causes of PAI are autoimmune destruction of the adrenal cortex in adults and CAH in children. These etiologies can be screened for using 21-hydroxylase antibodies and a baseline serum 17hydroxyprogesterone level. Males with negative 21-hydroxylase antibodies should be tested for adrenoleukodystrophy with plasma VLCFAs. If these diagnoses are excluded, a CT scan of the adrenals may reveal evidence of adrenal infiltrative processes or metastases. The individual's clinical picture and family history may render some steps in the algorithm redundant or suggest specific genetic syndromes. The latter includes subtypes of autoimmune polyglandular syndromes or specific rare genetic disorders where adrenal failure is part of a broader phenotype. A list of differential diagnoses is provided in Table 2. AHC, adrenal hypoplasia congenita; AI, adrenal insufficiency; VLCFA, very long chain fatty acid. a 17-OHprogesterone > 1000 ng/dL is diagnostic for 21-OH deficiency (14). b VLCFA should be measured in the initial evaluation of preadolescent boys. [Adapted from E. S. Husebye, et al: Consensus statement on the diagnosis, treatment and follow-up of patients with primary adrenal insufficiency. J Intern Med . 2014;275:104-115 (181), with permission. © John Wiley & Sons, Inc.]](https://figures.cochat.ai/paper-figures/3d28d00e3ab049b5b513e655fd2f1f7a/diagnosis-and-treatment-of-primary-adrenal-insufficiency-an-endocrine-society-figure-1.png)
Verification
Claims the paper makes
35 Valid · 2 Not valid · 109 Not checked · 48 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“However, in all these reports, adrenal crisis was a significant cause of death.”
§ Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline > Evidence
What the sources say
- Disputedcites [149] 149. Bergthorsdottir R, Leonsson-Zachrisson M, Odén A, Johannsson G. Premature mortality in patients with Addison's disease: a pop- ulation-based study. J Clin Endocrinol Metab. 2006;91:4849 - 4853. sourceExperimental — accuracy not yet measured
The Mortality section reports 36 deaths attributed to adrenal insufficiency but explicitly says that no patient was reported to have died from adrenal crisis under ICD-10. It also cautions that ICD-9 cannot distinguish adrenal crisis from primary adrenal insufficiency, so the study does not establish crisis as a significant cause of death. (LLM, conf=0.87)
Checked by a reasoning model — may be wrong.
- Not checked — no full text of the sourcecites [150] 150. Bensing S, Brandt L, Tabaroj F, et al. Increased death risk and altered cancer incidence pattern in patients with isolated or com- bined autoimmune primary adrenocortical insufficiency. Clin En- docrinol (Oxf). 2008;69:697-704. source
- Not checked — no full text of the sourcecites [7] 7. Erichsen MM, Løvås K, Fougner KJ, et al. Normal overall mortality rate in Addison's disease, but young patients are at risk of prema- ture death. Eur J Endocrinol. 2009;160:233-237. source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“In addition to a paired sample of cortisol and ACTH, the adrenal reserve is appropriately and safely assessed in pregnancy by corticotropin stimulation, if indicated (40,41).”
§ Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline > Evidence
What the sources say
- Supportedcites [40] 40. Lebbe M, Arlt W. What is the best diagnostic and therapeutic management strategy for an Addison patient during pregnancy? Clin Endocrinol (Oxf). 2013;78:497-502. source
The Investigations section (p. 3) calls the short Synacthen test a valid measure of adrenal cortisol reserve, including in pregnancy, and says there is no medical reason to avoid a single diagnostic dose in a pregnant woman. The Summary (p. 1) recommends the test when clinically feasible, alongside paired cortisol and ACTH measurements. (LLM, conf=0.94)
- Not checked — no full text of the sourcecites [41] 41. Suri D, Moran J, Hibbard JU, Kasza K, Weiss RE. Assessment of adrenal reserve in pregnancy: defining the normal response to the adrenocorticotropin stimulation test. J Clin Endocrinol Metab. 2006;91:3866 -3872. source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Patients with diseases such as nephrotic syndrome (43) and liver disease (50) as well as those who are in the immediate postoperative period (51) or who require intensive care (52) may have lower CBG and albumin and hence, lower cortisol measurements.”
§ Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline > Evidence
What the sources say
- Not checked — no full text of the sourcecites [43] 43. Klose M, Lange M, Rasmussen AK, et al. Factors influencing the adrenocorticotropin test: role of contemporary cortisol assays, body composition, and oral contraceptive agents. J Clin Endocri- nol Metab. 2007;92:1326 -1333. source
- Not checked — no full text of the sourcecites [50] 50. Vincent RP, Etogo-Asse FE, Dew T, Bernal W, Alaghband-Zadeh J, le Roux CW. Serum total cortisol and free cortisol index give different information regarding the hypothalamus-pituitary-adre- nal axis reserve in patients with liver impairment. Ann Clin Biochem. 2009;46:505-507. source
- Supportedcites [51] 51. le Roux CW, Chapman GA, Kong WM, Dhillo WS, Jones J, Alagh- band-Zadeh J. Free cortisol index is better than serum total cortisol in determining hypothalamic-pituitary-adrenal status in patients undergoing surgery. J Clin Endocrinol Metab. 2003;88:2045- 2048. source
For the part attributed to this source—the immediate postoperative period—the Results report that albumin and CBG fell after surgery, and that seven patients had unexpectedly low postoperative total cortisol. The Discussion attributes those low cortisol values to the fall in CBG. The other conditions in the citing sentence have separate citations. (LLM, conf=0.90)
- Not checked — no full text of the sourcecites [52] 52. Hamrahian AH, Oseni TS, Arafah BM. Measurements of serum free cortisol in critically ill patients. N Engl J Med. 2004;350: 1629 -1638. source
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Interpretation of the diagnostic results requires thorough consideration of pregnancy-associated physiological changes of adrenocortical function (42).”
§ Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline > Evidence
What the sources say
- Supportedcites [42] 42. Jung C, Ho JT, Torpy DJ, et al. A longitudinal study of plasma and urinary cortisol in pregnancy and postpartum. J Clin Endocrinol Metab. 2011;96:1533-1540. source
The Discussion (page not specified in the supplied passage) says that physiological hypercortisolism can be difficult to distinguish from Cushing’s syndrome during pregnancy and emphasizes trimester-specific reference ranges. This supports considering pregnancy-related adrenocortical changes when interpreting diagnostic results. (LLM, conf=0.92)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“An elevated ACTH concentration in the presence of a cortisol in the normal range can be the first sign of early-stage PAI (68).”
§ Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline > Evidence
What the sources say
- Could not verifycites [68] 68. Baker PR, Baschal EE, Fain PR, et al. Haplotype analysis discrim- inates genetic risk for DR3-associated endocrine autoimmunity and helps define extreme risk for Addison's disease. J Clin Endo- crinol Metab. 2010;95:E263-E270. sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) says that 21-hydroxylase autoantibodies usually precede overt Addison’s disease and proposes subsequent adrenal-function testing. Neither that passage nor the passages retrieved by searching for ACTH, cortisol, and early adrenal insufficiency addresses whether elevated ACTH with normal-range cortisol can be an early sign of PAI. (LLM, conf=0.73)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
118 more claims · 24 with their cited sources checked
Create a free account to see all 194 claims and every source verdict.
- Probably not a substantial claim. 22
- It may state two separate claims as one. 58
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“In children, glucocorticoid replacement therapy (GCCrt) should be started with hydrocortisone (HC) at a total daily dose of 10 mg/m2, with dose titration according to individual needs (35).”
From X-linked adrenoleukodystrophy and primary adrenal insufficiency (2023) · cites this paper as [35]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“no drug suitably mimics the diurnal pattern of cortisol”
From Modeling Congenital Adrenal Hyperplasia and Testing Interventions for Adrenal Insufficiency Using Donor-Specific Reprogrammed Cells (2018) · cites this paper as Bornstein et al., 2016
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In such cases, a GC dosage increase of 20% to 40% from the 24th week onward is often beneficial (215).”
From Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society* Clinical Practice Guideline (2018) · cites this paper as [215]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Nevertheless, no consensus exists regarding the optimal dose and hydrocortisone delivery mode during major stress, and current recommendations are empirical rather than evidence-based (7, 17).”
From Prevention of adrenal crisis: cortisol responses to major stress compared to stress dose hydrocortisone delivery (2020) · cites this paper as [17]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In primary and secondary adrenal insufficiency, peak cortisol levels < 500 nmol/L (< 18.1 μg/dL), depending on assay, are indicative of adrenal insufficiency (38, 39).”
From European Society of Endocrinology and Endocrine Society Joint Clinical Guideline: Diagnosis and Therapy of Glucocorticoid-induced Adrenal Insufficiency (2024) · cites this paper as [38]
Experimental — accuracy not yet measured
25 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline > 2.2
“We suggest the low-dose (1 g) corticotropin test for diagnosis of PAI only when the substance itself is in short supply.”
§ Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline > Evidence
“Thus, for practical reasons, the low-dose test may be applicable to situations when corticotropin is in short supply or for other structural or economic reasons.”
Citations
Cites
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477 · cited 1×
“The Task Force followed the approach recommended by the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) group, an international group with expertise in development of evidence-based guidelines (15).”
MethodSapolsky, R. M., Romero, L. M., & Munck, A. U. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.1.0389 · Cited by 7,541 · cited 1×
“Enhanced glucocorticoid secretion in critical illness is considered necessary to prevent defense mechanisms (eg, cytokine release) from overshooting with concomitant detrimental toxicity (142, 143).”
BackgroundSapolsky, R. M. (2000) · Endocrine Reviews · doi:10.1210/er.21.1.55 · Cited by 7,533
The Molecular Biology, Biochemistry, and Physiology of Human Steroidogenesis and Its Disorders
Miller, W. L., & Auchus, R. J. (2011) · Endocrine Reviews · doi:10.1210/er.2010-0013 · Cited by 2,458 · cited 1×
“In newborns and children, mineralocorticoid sensitivity is lower, thereby usually requiring higher fludrocortisone doses compared to adults (106).”
BackgroundSpeiser, P. W., Azziz, R., Baskin, L. S., Ghizzoni, L., Hensle, T. W., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Montori, V. M., Oberfield, S. E., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2631 · Cited by 1,468 · cited 4×
“a 17-OHprogesterone 1000 ng/dL is diagnostic for 21-OH deficiency (14).”
BackgroundMethodInfluentialSelf-citationORENTREICH, N., BRIND, J. L., RIZER, R. L., & VOGELMAN, J. H. (1984) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-59-3-551 · Cited by 1,349 · cited 1×
“Serum DHEAS concentrations physiologically peak between ages 20 and 30 years, followed by a gradual decline that is independent of menopause (113).”
BackgroundSpeiser, P. W., Arlt, W., Auchus, R. J., Baskin, L. S., Conway, G. S., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Murad, M. H., Oberfield, S. E., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01865 · Cited by 1,234
Self-citationCorticosteroid insufficiency in acutely ill patients
Cooper, M. S., & Stewart, P. M. (2003) · New England Journal of Medicine · doi:10.1056/nejmra020529 · Cited by 1,033
Marik, P. E., Pastores, S. M., Annane, D., Meduri, G. U., Sprung, C. L., Arlt, W., Keh, D., Briegel, J., Beishuizen, A., Dimopoulou, I., et al. (2008) · Critical Care Medicine · doi:10.1097/ccm.0b013e31817603ba · Cited by 912 · cited 1×
“Although similar arguments for the utility of the low-dose test have been proposed for other special diagnostic challenges such as the detection of adrenal insufficiency in critically ill patients (critical illness-related corticosteroid insufficiency), more evidence is needed to support such a formal recommendation (…”
BackgroundSelf-citationPharmacokinetics and pharmacodynamics of systemically administered glucocorticoids.
Czock, D., Keller, F., Rasche, F. M., & H??ussler, U. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544010-00003 · Cited by 886 · cited 1×
“Because of the short plasma half-life of hydrocortisone (approximately 90 min) (90), multiple dosing is recommended to mimic physiological conditions.”
Background
Research works printed but not linked: 3
- [29]29. Dorin RI, Qualls CR, Crapo LM. Diagnosis of adrenal insuffi- ciency. Ann Intern Med. 2003;139:194 -204.
- [110]110. Keilholz U, Guthrie GP Jr. Adverse effect of phenytoin on miner- alocorticoid replacement with fludrocortisone in adrenal insuffi- ciency. Am J Med Sci. 1986;291:280 -283.
- [177]177. Gan EH, MacArthur K, Mitchell AL, et al. Residual adrenal func- tion in autoimmune Addison's disease: improvement after tetra- cosactide (ACTH1-24) treatment. J Clin Endocrinol Metab. 2014; 99:111-118.
Cited by
Brahmer, J. R., Lacchetti, C., Schneider, B. J., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., Ernstoff, M. S., Gardner, J. M., Ginex, P., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.6385 · Cited by 3,713
“Fludrocortisone is needed in addition to hydrocortisone in most cases of primary adrenal insufficiency, which involves the loss of mineralocorticoid as well as glucocorticoid, leading to more-profound blood pressure and electrolyte abnormalities.(63) Monitoring is also affected by localization, as pituitary hormones a…”
BackgroundSchneider, B. J., Naidoo, J., Santomasso, B. D., Lacchetti, C., Adkins, S., Anadkat, M., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01440 · Cited by 2,372
Fassnacht, M., Arlt, W., Bancos, I., Dralle, H., Newell-Price, J., Sahdev, A., Tabarin, A., Terzolo, M., Tsagarakis, S., & Dekkers, O. M. (2016) · European Journal of Endocrinology · doi:10.1530/eje-16-0467 · Cited by 1,566
Self-citationSpeiser, P. W., Arlt, W., Auchus, R. J., Baskin, L. S., Conway, G. S., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Murad, M. H., Oberfield, S. E., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01865 · Cited by 1,234
Self-citationWeiss, S. L., Peters, M. J., Alhazzani, W., Agus, M. S. D., Flori, H. R., Inwald, D. P., Nadel, S., Schlapbach, L. J., Tasker, R. C., Argent, A. C., et al. (2020) · Pediatric Critical Care Medicine · doi:10.1097/pcc.0000000000002198 · Cited by 1,228
Fassnacht, M., Dekkers, O. M., Else, T., Baudin, E., Berruti, A., de Krijger, R. R., Haak, H. R., Mihai, R., Assie, G., & Terzolo, M. (2018) · European Journal of Endocrinology · doi:10.1530/eje-18-0608 · Cited by 961
Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline
Fleseriu, M., Hashim, I. A., Karavitaki, N., Melmed, S., Murad, M. H., Salvatori, R., & Samuels, M. H. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2118 · Cited by 945
Self-citationBrahmer, J. R., Abu-Sbeih, H., Ascierto, P. A., Brufsky, J., Cappelli, L. C., Cortazar, F. B., Gerber, D. E., Hamad, L., Hansen, E., Johnson, D. B., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002435 · Cited by 917
Fassnacht, M., Tsagarakis, S., Terzolo, M., Tabarin, A., Sahdev, A., Newell-Price, J., Pelsma, I., Marina, L., Lorenz, K., Bancos, I., et al. (2023) · European Journal of Endocrinology · doi:10.1093/ejendo/lvad066 · Cited by 786
“262 If only one adrenal metastasis is present, primary adrenal insufficiency is extremely unlikely and usually no specific assessment of adrenal reserve is required.”
BackgroundSelf-citationCongenital adrenal hyperplasia
El-Maouche, D., Arlt, W., & Merke, D. P. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31431-9 · Cited by 669
Self-citationWeiss, S. L., Peters, M. J., Alhazzani, W., Agus, M. S. D., Flori, H. R., Inwald, D. P., Nadel, S., Schlapbach, L. J., Tasker, R. C., Argent, A. C., et al. (2020) · Intensive Care Medicine · doi:10.1007/s00134-019-05878-6 · Cited by 606
Congenital Adrenal Hyperplasia—Current Insights in Pathophysiology, Diagnostics, and Management
Claahsen - van der Grinten, H. L., Speiser, P. W., Ahmed, S. F., Arlt, W., Auchus, R. J., Falhammar, H., Flück, C. E., Guasti, L., Huebner, A., Kortmann, B. B. M., et al. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab016 · Cited by 556
Self-citationEndocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints
Chang, L.-S., Barroso-Sousa, R., Tolaney, S. M., Hodi, F. S., Kaiser, U. B., & Min, L. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00006 · Cited by 532
Endocrine toxicities of immune checkpoint inhibitors
Wright, J. J., Powers, A. C., & Johnson, D. B. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00484-3 · Cited by 441
Measuring cortisol in serum, urine and saliva—Are our assays good enough?
El-Farhan, N., Rees, D. A., & Evans, C. (2017) · Annals of Clinical Biochemistry: International Journal of Laboratory Medicine · doi:10.1177/0004563216687335 · Cited by 395
“The gold standard test of HPA axis function is the insulin tolerance test (ITT) in which insulin-induced hypoglycaemia stimulates the hypothalamus, resulting in CRH release and an increase in serum cortisol.(14) The short Synacthen test (SST) is a quick and safe alternative to the ITT and has replaced it as the first…”
BackgroundMethodInfluentialHusebye, E. S., Pearce, S. H., Krone, N. P., & Kämpe, O. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00136-7 · Cited by 378
Self-citationAnnane, D., Pastores, S. M., Rochwerg, B., Arlt, W., Balk, R. A., Beishuizen, A., Briegel, J., Carcillo, J., Christ-Crain, M., Cooper, M. S., et al. (2017) · Intensive Care Medicine · doi:10.1007/s00134-017-4919-5 · Cited by 371
“We found one single-center randomized trial that compared low-dose ACTH (1 μg) stimulation test with total random cortisol for diagnosis of adrenal insufficiency in 59 adults with septic shock [10].”
BackgroundSelf-citationCongenital adrenal hyperplasia due to 21-hydroxylase deficiency
Merke, D. P., & Auchus, R. J. (2020) · New England Journal of Medicine · doi:10.1056/nejmra1909786 · Cited by 341
Self-citationAnnane, D., Pastores, S. M., Rochwerg, B., Arlt, W., Balk, R. A., Beishuizen, A., Briegel, J., Carcillo, J., Christ-Crain, M., Cooper, M. S., et al. (2017) · Critical Care Medicine · doi:10.1097/ccm.0000000000002737 · Cited by 330
Self-citationHair cortisol analysis: An update on methodological considerations and clinical applications
Greff, M. J. E., Levine, J. M., Abuzgaia, A. M., Elzagallaai, A. A., Rieder, M. J., & van Uum, S. H. M. (2019) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2018.09.010 · Cited by 260
Rushworth, R. L., Torpy, D. J., & Falhammar, H. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1807486 · Cited by 262
Self-citationStress, hypothalamic–pituitary–adrenal axis, hypothalamic–pituitary–gonadal axis, and aggression.
Mbiydzenyuy, N. E., & Qulu, L.-A. (2024) · Metabolic Brain Disease · doi:10.1007/s11011-024-01393-w · Cited by 255
“However, under stress conditions, secretion may increase 10-to 12-fold (Bornstein et al. 2016 ).”
BackgroundSklar, C. A., Antal, Z., Chemaitilly, W., Cohen, L. E., Follin, C., Meacham, L. R., & Murad, M. H. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01175 · Cited by 224
Self-citationHahner, S., Ross, R. J., Arlt, W., Bancos, I., Burger-Stritt, S., Torpy, D. J., Husebye, E. S., & Quinkler, M. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00252-7 · Cited by 223
Self-citationCongenital adrenal hyperplasia
Auer, M. K., Nordenström, A., Lajic, S., & Reisch, N. (2023) · The Lancet · doi:10.1016/s0140-6736(22)01330-7 · Cited by 215
Isidori, A. M., Venneri, M. A., Graziadio, C., Simeoli, C., Fiore, D., Hasenmajer, V., Sbardella, E., Gianfrilli, D., Pozza, C., Pasqualetti, P., et al. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30398-4 · Cited by 211
Treating the Side Effects of Exogenous Glucocorticoids; Can We Separate the Good From the Bad?
Pofi, R., Caratti, G., Ray, D. W., & Tomlinson, J. W. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnad016 · Cited by 209
“In endocrine disease, prescribed GCs are used for the diagnosis of Cushing’s syndrome (mainly dexametha - sone), but, more importantly, they are crucial for the management of adrenal insufficiency (11) and congenital adrenal hyperplasia (CAH) (12 ).”
BackgroundThe cortisol stress response induced by surgery: A systematic review and meta‐analysis
Prete, A., Yan, Q., Al‐Tarrah, K., Akturk, H. K., Prokop, L. J., Alahdab, F., Foster, M. A., Lord, J. M., Karavitaki, N., Wass, J. A., et al. (2018) · Clinical Endocrinology · doi:10.1111/cen.13820 · Cited by 192
Self-citationHusebye, E. S., Castinetti, F., Criseno, S., Curigliano, G., Decallonne, B., Fleseriu, M., Higham, C. E., Lupi, I., Paschou, S. A., Toth, M., et al. (2022) · European Journal of Endocrinology · doi:10.1530/eje-22-0689 · Cited by 192
Self-citationMazziotti, G., Frara, S., & Giustina, A. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00005 · Cited by 181
Javorsky, B. R., Raff, H., Carroll, T. B., Algeciras-Schimnich, A., Singh, R. J., Colón-Franco, J. M., & Findling, J. W. (2021) · Journal of the Endocrine Society · doi:10.1210/jendso/bvab022 · Cited by 171
“Patients with primary AI always have an elevated plasma ACTH, so CST is typically not needed for confirmation of the diagnosis [5, 6].”
BackgroundWoodcock, T., Barker, P., Daniel, S., Fletcher, S., Wass, J. A. H., Tomlinson, J. W., Misra, U., Dattani, M., Arlt, W., & Vercueil, A. (2020) · Anaesthesia · doi:10.1111/anae.14963 · Cited by 163
“In 2016, the Endocrine Society USA released a clinical guideline, focusing on primary adrenal insufficiency [6], with detailed recommendations on stress dosing in the adult patient and the paediatric setting.”
BackgroundSelf-citationLong-Term Endocrine and Metabolic Consequences of Cancer Treatment: A Systematic Review
Gebauer, J., Higham, C., Langer, T., Denzer, C., & Brabant, G. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00092 · Cited by 161
Late endocrine effects of childhood cancer
Rose, S. R., Horne, V. E., Howell, J. C., Lawson, S. A., Rutter, M. M., Trotman, G. E., & Corathers, S. D. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.45 · Cited by 168
Glucocorticoid induced adrenal insufficiency
Prete, A., & Bancos, I. (2021) · BMJ · doi:10.1136/bmj.n1380 · Cited by 155
Huffnagel, I. C., Laheji, F. K., Aziz-Bose, R., Tritos, N. A., Marino, R., Linthorst, G. E., Kemp, S., Engelen, M., & Eichler, F. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01307 · Cited by 147
“The first criterion was an abnormal cortisol response after standard dose (250 mg) intravenous (or intramuscular) cosyntropin stimulation (5).”
Beuschlein, F., Else, T., Bancos, I., Hahner, S., Hamidi, O., van Hulsteijn, L., Husebye, E. S., Karavitaki, N., Prete, A., Vaidya, A., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae250 · Cited by 172
Self-citationSyndrome of Inappropriate Antidiuresis: From Pathophysiology to Management
Warren, A. M., Grossmann, M., Christ‐Crain, M., & Russell, N. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnad010 · Cited by 184
Epidemiology, pathogenesis, and diagnosis of Addison’s disease in adults
Betterle, C., Presotto, F., & Furmaniak, J. (2019) · Journal of Endocrinological Investigation · doi:10.1007/s40618-019-01079-6 · Cited by 161
“Adrenal imaging is not required in patients with AAD positive for ACA/21-OHAbs [6, 54, 159] (Fig.”
BackgroundInfluentialThe Glucocorticoid Receptor: Isoforms, Functions, and Contribution to Glucocorticoid Sensitivity
Lockett, J., Inder, W. J., & Clifton, V. L. (2024) · Endocrine Reviews · doi:10.1210/endrev/bnae008 · Cited by 135
Perioperative Steroid Management: Approaches Based on Current Evidence
Liu, M. M., Reidy, A. B., Saatee, S., & Collard, C. D. (2017) · Anesthesiology · doi:10.1097/aln.0000000000001659 · Cited by 126
Adrenal crisis: prevention and management in adult patients
Dineen, R., Thompson, C. J., & Sherlock, M. (2019) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018819848218 · Cited by 123
Cushing’s Syndrome in Pediatrics
Lodish, M. B., Keil, M. F., & Stratakis, C. A. (2018) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2018.02.008 · Cited by 116
Self-citationBarroso‐Sousa, R., Ott, P. A., Hodi, F. S., Kaiser, U. B., Tolaney, S. M., & Min, L. (2018) · Cancer · doi:10.1002/cncr.31200 · Cited by 113
“Patients with either primary or central hypocortisolism must receive hormone replacement according to the current guidelines.(51) The management of AI, including adrenal crisis, is presented in Table 1.”
MethodImpact of COVID-19 on the Endocrine System: A Mini-review
Clarke, S. A., Abbara, A., & Dhillo, W. S. (2021) · Endocrinology · doi:10.1210/endocr/bqab203 · Cited by 122
“Symptoms of fatigue (65), postural hypotension, and cognitive impairment are frequently reported by patients with long COVID as well as by patients with adrenal insufficiency (66, 67).”
BackgroundBeuschlein, F., Else, T., Bancos, I., Hahner, S., Hamidi, O., van Hulsteijn, L. T., Husebye, E. S., Karavitaki, N., Prete, A., Vaidya, A., et al. (2024) · European Journal of Endocrinology · doi:10.1093/ejendo/lvae029 · Cited by 156
Self-citationENDOCRINOLOGY IN THE TIME OF COVID-19: Management of adrenal insufficiency
Arlt, W., Baldeweg, S. E., Pearce, S. H. S., & Simpson, H. L. (2020) · European Journal of Endocrinology · doi:10.1530/eje-20-0361 · Cited by 107
Self-citationModified-Release Hydrocortisone in Congenital Adrenal Hyperplasia
Merke, D. P., Mallappa, A., Arlt, W., Brac de la Perriere, A., Lindén Hirschberg, A., Juul, A., Newell-Price, J., Perry, C. G., Prete, A., Rees, D. A., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab051 · Cited by 109
“Age, y, median (range) 35 (19-61) 40 (19-68) 35 (20-67)”
BackgroundSelf-citationEndocrine Responses to Critical Illness: Novel Insights and Therapeutic Implications
Boonen, E., & Van den Berghe, G. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-4115 · Cited by 105
An Update on Addison’s Disease
Barthel, A., Benker, G., Berens, K., Diederich, S., Manfras, B. J., Grüber, M., Kanczkowski, W., Kline, G. A., Kamvissi, V., Hahner, S., et al. (2018) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-0804-2715 · Cited by 135
“Hyponatraemia, hyperkalaemia and - especially in children hypoglycaemia are key lab characteristics of the disease reflecting the deficiency of gluco- and mineralocorticoids [27].”
BackgroundMethodInfluentialSelf-citationYanase, T., Tajima, T., Katabami, T., Iwasaki, Y., Tanahashi, Y., Sugawara, A., Hasegawa, T., Mune, T., Oki, Y., Nakagawa, Y., et al. (2016) · Endocrine Journal · doi:10.1507/endocrj.ej16-0242 · Cited by 104
Endocrine problems in the critically ill 2: endocrine emergencies
Kerr, D. E., Wenham, T., & Newell-Price, J. D. C. (2017) · BJA Education · doi:10.1093/bjaed/mkx023 · Cited by 102
“injection, based on specialist endocrinology advice.(3) Cautious fluid resuscitation (typically 2–3 litre isotonic crystalloid) is usually required.”
BackgroundMethodInfluentialAdrenal insufficiency: Physiology, clinical presentation and diagnostic challenges
Martin‐Grace, J., Dineen, R., Sherlock, M., & Thompson, C. J. (2020) · Clinica Chimica Acta · doi:10.1016/j.cca.2020.01.029 · Cited by 128
Arlt, W., & _, _. (2016) · Endocrine Connections · doi:10.1530/ec-16-0054 · Cited by 101
Self-citationESE Clinical Practice Guideline on functioning and nonfunctioning pituitary adenomas in pregnancy
Luger, A., Broersen, L. H. A., Biermasz, N. R., Biller, B. M. K., Buchfelder, M., Chanson, P., Jørgensen, J. O. L., Keleştimur, F., Llahana, S., Maiter, D. M., et al. (2021) · European Journal of Endocrinology · doi:10.1530/eje-21-0462 · Cited by 112
Mazziotti, G., Formenti, A. M., Frara, S., Roca, E., Mortini, P., Berruti, A., & Giustina, A. (2017) · European Journal of Endocrinology · doi:10.1530/eje-17-0154 · Cited by 96
Prete, A., Taylor, A. E., Bancos, I., Smith, D. J., Foster, M. A., Kohler, S., Fazal-Sanderson, V., Komninos, J., O’Neil, D. M., Vassiliadi, D. A., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa133 · Cited by 96
Self-citationSerum cortisol: an up-to-date assessment of routine assay performance
Hawley, J. M., Owen, L. J., Lockhart, S. J., Monaghan, P. J., Armston, A., Chadwick, C. A., Wilshaw, H., Freire, M., Perry, L., & Keevil, B. G. (2016) · Clinical Chemistry · doi:10.1373/clinchem.2016.255034 · Cited by 95
El-Maouche, D., Hargreaves, C. J., Sinaii, N., Mallappa, A., Veeraraghavan, P., & Merke, D. P. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00208 · Cited by 93
“The Endocrine Society clinical practice guidelines for the management of CAH (4) and primary adrenal insufficiency (1) suggest judicious use of glucocorticoid in NC patients, and even mild cortisol impairment generally does not lead to Addisonian crisis (1, 17, 18).”
BackgroundSelf-citationThe adrenal gland in stress – Adaptation on a cellular level
Berger, I., Werdermann, M., Bornstein, S. R., & Steenblock, C. (2019) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2019.04.006 · Cited by 110
Self-citationPrimary adrenal insufficiency: New genetic causes and their long‐term consequences
Buonocore, F., & Achermann, J. C. (2019) · Clinical Endocrinology · doi:10.1111/cen.14109 · Cited by 101
Exploring inpatient hospitalizations and morbidity in patients with adrenal insufficiency
Stewart, P. M., Biller, B. M. K., Marelli, C., Gunnarsson, C., Ryan, M. P., & Johannsson, G. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2221 · Cited by 90
Adrenal crises: perspectives and research directions
Rushworth, R. L., Torpy, D. J., & Falhammar, H. (2016) · Endocrine · doi:10.1007/s12020-016-1204-2 · Cited by 100
Self-citationLee, M. A., Wang, S., Jin, X., Bakh, N. A., Nguyen, F. T., Dong, J. I., Silmore, K. S., Gong, X., Pham, C., Jones, K. K., et al. (2020) · Advanced Healthcare Materials · doi:10.1002/adhm.202000429 · Cited by 83
SIMBA: using Kolb’s learning theory in simulation-based learning to improve participants’ confidence
Davitadze, M., Ooi, E., Ng, C. Y., Zhou, D., Thomas, L., Hanania, T., Blaggan, P., Evans, N., Chen, W., Melson, E., et al. (2022) · BMC Medical Education · doi:10.1186/s12909-022-03176-2 · Cited by 107
Self-citationThe Impact of SARS-Cov-2 Virus Infection on the Endocrine System
Somasundaram, N. P., Ranathunga, I., Ratnasamy, V., Wijewickrama, P. S. A., Dissanayake, H. A., Yogendranathan, N., Gamage, K. K. K., de Silva, N. L., Sumanatilleke, M., Katulanda, P., et al. (2020) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaa082 · Cited by 91
“Severe pneumonia or any features of acute adrenal insufficiency would warrant IV or IM hydrocortisone treatment with 100 mg given immediately, followed by 200 mg every 24 hours as a continuous IV infusion or 6-hourly in divided doses, accompanied with appropriate fluid resuscitation [66].”
BackgroundTherapy options for adrenal insufficiency and recommendations for the management of adrenal crisis
(MTG1), O. B. O. E. E., Nowotny, H. F., Ahmed, S. F., Bensing, S., Beun, J. G., Brösamle, M., Chifu, I. O., der Grinten, H. L. C., Clemente, M., Falhammar, H., et al. (2021) · Endocrine · doi:10.1007/s12020-021-02649-6 · Cited by 104
Self-citationGuidance for the prevention and emergency management of adult patients with adrenal insufficiency
Simpson, H., Tomlinson, J., Wass, J., Dean, J., & Arlt, W. (2020) · Clinical Medicine · doi:10.7861/clinmed.2019-0324 · Cited by 78
Self-citationOpioid-Induced Adrenal Insufficiency
Donegan, D., & Bancos, I. (2018) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2018.04.010 · Cited by 78
“Alternatively, new oral formulations using delayed and sustained-release multiparticulate tablets (Chronocort, Diurnal Group PLC) or immediate release with a sustained-release core (Plenadren, Shire) to better resemble a physiologic profile have been developed but are currently under study.(31) It is worth noting that…”
BackgroundInfluentialPrimary adrenal insufficiency in children: Diagnosis and management
Kırkgöz, T., & Güran, T. (2018) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2018.05.010 · Cited by 90
Al Alawi, A. M., Nordenström, A., & Falhammar, H. (2019) · Endocrine · doi:10.1007/s12020-018-01835-3 · Cited by 77
Decker, A. M., Kapila, Y. L., & Wang, H. (2021) · Periodontology 2000 · doi:10.1111/prd.12381 · Cited by 105
Cadegiani, F. A., & Kater, C. E. (2017) · Sports Medicine - Open · doi:10.1186/s40798-017-0113-0 · Cited by 76
“peripheral and central components of the HPA axis (primary or peripheral: adrenal; central: pituitary and hypothalamus), with cosyntropin stimulation test, that directly evaluates adrenal responses to synthetic ACTH [32], insulin tolerance test (ITT), which evaluates the integrity of the HPA axis [33], and salivary co…”
BackgroundMethodRivero, J. D., Cordes, L. M., Kłubo-Gwieździńska, J., Madan, R. A., Nieman, L. K., & Gulley, J. L. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0470 · Cited by 81
Hurtado, M. D., Cortes, T., Natt, N., Young, W. F., & Bancos, I. (2018) · Clinical Endocrinology · doi:10.1111/cen.13803 · Cited by 76
Human studies on hypothalamo-pituitary-adrenal (HPA) axis
Liyanarachchi, K., Ross, R. J. M., & Debono, M. (2017) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2017.10.011 · Cited by 98
Flück, C. E. (2017) · European Journal of Endocrinology · doi:10.1530/eje-17-0128 · Cited by 75
Normal Adrenal and Thyroid Function in Patients Who Survive COVID-19 Infection
Clarke, S. A., Phylactou, M., Patel, B., Mills, E., Muzi, B., Izzi‐Engbeaya, C. N., Choudhury, S., Khoo, B. C. E., Meeran, K. M., Comninos, A. N., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab349 · Cited by 78
“Participants were considered to have an adequate response to Synacthen if they reached a peak cortisol value of ≥ 450 nmol/L and increment by ≥150 nmol/L from baseline, either at 30 or 60 minutes after Synacthen (18, 25).”
BackgroundMethodInfluentialPhilpott, H., Dougherty, M., Reed, C. C., Caldwell, M., Kirk, D., Torpy, D. J., & Dellon, E. S. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14573 · Cited by 81
“Regarding the optimal means for assessment of adrenal insufficiency, Endocrine Society Guidelines for primary adrenal insufficiency recommend the high dose (250 mcg) ACTH-stimulation test.(41) While the LDST may have a higher sensitivity for detection of biochemical adrenal insufficiency, this has not been proven, and…”
BackgroundSelf-citationCentral adrenal insufficiency in children and adolescents
Patti, G., Guzzeti, C., Di Iorgi, N., Maria Allegri, A. E., Napoli, F., Loche, S., & Maghnie, M. (2018) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2018.03.012 · Cited by 75
Autoimmune Addison's disease – An update on pathogenesis
Hellesen, A., Bratland, E., & Husebye, E. S. (2018) · Annales d Endocrinologie · doi:10.1016/j.ando.2018.03.008 · Cited by 91
Self-citationHow we treat endocrine complications of immune checkpoint inhibitors
Paschou, S. Α., Stefanaki, K., Ψαλτοπούλου, Θ., Liontos, M., Koutsoukos, K., Zagouri, F., Lambrinoudaki, I. V., & Dimopoulos, M. A. (2021) · ESMO Open · doi:10.1016/j.esmoop.2020.100011 · Cited by 81
Investigation of the Hypothalamo-pituitary-adrenal (HPA) axis: a contemporary synthesis
Karaca, Z., Grossman, A. B., & Keleştimur, F. (2021) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-020-09611-3 · Cited by 83
“Unlike primary adrenal insufficiency (PAI), SAI demonstrates a less severe clinical presentation due to the sparing of aldosterone secretion, and additionally lacks the findings of hyperpigmentation and marked hyperkalaemia.”
InfluentialThe short cosyntropin test revisited: new normal reference range using LC-MS/MS
Ueland, G. Å., Methlie, P., Øksnes, M., Thordarson, H. B., Sagen, J., Kellmann, R., Mellgren, G., Ræder, M., Dahlqvist, P., Dahl, S. R., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-02602 · Cited by 71
Self-citationS2k-Leitlinie zur fachärztlichen Diagnostik und Therapie von Asthma 2023
Lommatzsch, M., Criée, C.-P., de Jong, C. C. M., Gappa, M., Geßner, C., Gerstlauer, M., Hämäläinen, N., Haidl, P., Hamelmann, E. H., Horak, F., et al. (2023) · Pneumologie · doi:10.1055/a-2070-2135 · Cited by 119
Fixing the broken clock in adrenal disorders: focus on glucocorticoids and chronotherapy
Minnetti, M., Hasenmajer, V., Pofi, R., Venneri, M. A., Alexandraki, K. I., & Isidori, A. M. (2020) · Journal of Endocrinology · doi:10.1530/joe-20-0066 · Cited by 70
Glucocorticoids and cognitive function: a walkthrough in endogenous and exogenous alterations
Alcubierre, D. D., Ferrari, D., Mauro, G. C. D., Isidori, A. M., Tomlinson, J., & Pofi, R. (2023) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02091-7 · Cited by 78
“Patients with primary AI require GC and MC replacement therapy, whereas individuals with secondary and tertiary AI usually necessitate only GC replacement [103–105].”
BackgroundAdrenal Insufficiency in Adults: A Review
Vaidya, A., Findling, J., & Bancos, I. (2025) · JAMA · doi:10.1001/jama.2025.5485 · Cited by 75
Pofi, R., Feliciano, C., Sbardella, E., Argese, N., Woods, C. P., Grossman, A. B., Jafar-Mohammadi, B., Gleeson, H., Lenzi, A., Isidori, A. M., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00529 · Cited by 67
Phase 3 Trial of Crinecerfont in Adult Congenital Adrenal Hyperplasia
Auchus, R. J., Hamidi, O., Pivonello, R., Bancos, I., Russo, G., Witchel, S. F., Isidori, A. M., Rodien, P., Srirangalingam, U., Kiefer, F. W., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2404656 · Cited by 79
Self-citationHome waking salivary cortisone to screen for adrenal insufficiency
Debono, M., Elder, C. J., Lewis, J., Fearnside, J., Caunt, S., Dixon, S., Jacques, R. M., Newell-Price, J., Whitaker, M. J., Keevil, B., et al. (2023) · NEJM Evidence · doi:10.1056/evidoa2200182 · Cited by 66
Redefining the stress cortisol response to surgery
Khoo, B., Boshier, P. R., Freethy, A., Tharakan, G., Saeed, S., Hill, N., Williams, E. L., Moorthy, K., Tolley, N., Jiao, L. R., et al. (2017) · Clinical Endocrinology · doi:10.1111/cen.13439 · Cited by 66
Ruiz-Babot, G., Balyura, M., Hadjidemetriou, I., Ajodha, S. J., Taylor, D. R., Ghataore, L., Taylor, N. F., Schubert, U., Ziegler, C. G., Storr, H. L., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.01.003 · Cited by 65
Self-citationCuesta, M., Garrahy, A., Slattery, D., Gupta, S., Hannon, A. M., Forde, H., McGurren, K., Sherlock, M., Tormey, W., & Thompson, C. J. (2016) · Clinical Endocrinology · doi:10.1111/cen.13128 · Cited by 65
Acute abdomen in the immunocompromised patient: WSES, SIS-E, WSIS, AAST, and GAIS guidelines
Coccolini, F., Improta, M., Sartelli, M., Rasa, H. K., Sawyer, R. G., Coimbra, R. S. M., Chiarugi, M., Litvin, A., Hardcastle, T. C., Forfori, F., et al. (2021) · World Journal of Emergency Surgery · doi:10.1186/s13017-021-00380-1 · Cited by 84
“followed by continued supplementation of 50 mg of hydrocortisone IV every 6 h [167].”
MethodBorresen, S. W., Klose, M., Baslund, B., Rasmussen, Å. K., Hilsted, L., Friis-Hansen, L., Locht, H., Hansen, A., Hetland, M. L., Lydolph, M. C., et al. (2017) · European Journal of Endocrinology · doi:10.1530/eje-17-0251 · Cited by 63
Kline, G., Buse, J., & Krause, R. (2017) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2017.02.008 · Cited by 62
Alexandraki, K., & Grossman, A. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8122153 · Cited by 62
“The last dose should be taken in at least 6 h away from bedtime to avoid sleep disorders or metabolic side-effects [8].”
BackgroundCasertano, A., Rossi, A., Fecarotta, S., Rosanio, F. M., Moracas, C., Candia, F. D., Parenti, G., Franzese, A., & Mozzillo, E. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.684011 · Cited by 71
“In PAI both glucocorticoids and mineralocorticoids synthesis are affected, while in CAI only glucocorticoid synthesis is compromised (53, 54).”
BackgroundAdrenoleukodystrophy: Guidance for adrenal surveillance in males identified by newborn screen
Regelmann, M. O., Kamboj, M. K., Miller, B. S., Nakamoto, J. M., Sarafoglou, K., Shah, S., Stanley, T. L., Marino, R., & Pediatric Endocrine Society Drug and Therapeutics/Rare Diseases Committee (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00920 · Cited by 61
Metadata
- Authors
- Bornstein, S. R., Allolio, B., Arlt, W., Barthel, A., Don-Wauchope, A., Hammer, G. D., Husebye, E. S., Merke, D. P., Murad, M. H., Stratakis, C. A., & Torpy, D. J.
- Affiliations
- King's College London (GB)
- Mayo Clinic (US)
- National Institutes of Health (US)
- Royal Adelaide Hospital (AU)
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2016-02
- Volume
- 101
- Issue
- 2
- Pages
- 364-389
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC4880116
- OpenAlex
- W2234917292
- Cited by
- 1,769
- References
- 222
- Citations by year
- 2026: 187 · 2025: 198 · 2024: 180 · 2023: 191 · 2022: 180 · 2021: 206 · 2020: 165 · 2019: 149 · 2018: 148 · 2017: 102 · 2016: 54
- FWCI
- 151.55
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, cc-by-nc)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
- Research Portal (King's College London) (submittedVersion, cc-by-nc-nd)
- Online Publication Service of Würzburg University (Würzburg University) (submittedVersion, cc-by-nc-nd)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- Spiral (Imperial College London) (submittedVersion, cc-by-nc-nd)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, cc-by-nc)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- European Society of Endocrinology
- Novo Nordisk Fonden (NNF14OC0011005)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK062027)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
- Keywords
- Addison's disease, diagnosis, hydrocortisone replacement, fludrocortisone, corticosteroid dose, stress dosing, 21-hydroxylase autoantibodies, autoimmune thyroid disease, pregnancy, glucocorticoid therapy, autoimmune adrenal insufficiency
- MeSH terms
- Adrenal Insufficiency, Female, Humans, Pregnancy, Societies, Medical, Evidence-Based Medicine, Hormone Replacement Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.